[Aspects of treatment of hypertrophic obstructive cardiomyopathy with emphasis on the role of percutaneous transluminal ablation of the myocardial septum].
The prevalence of hypertrophic cardiomyopathy is approximately 0.2% whereby the obstructive form accounts for one quarter. The basic treatment involves administration of negatively inotropic drugs (beta-blockers and/or verapamil), which reduce the intraventricular pressure gradient and have a positive impact on the symptomatology. In patients refractory or intolerant to medicamentous treatment surgical or catheterization is used. Percutaneous transluminal septal myocardial ablation reduces significantly the symptomatology of dyspnoea and stenocardia, increases load tolerance and improves the left ventricular diastolic function. In none of the mentioned therapeutic approaches so far a favourable effect on the prognosis of patients with a risk profile associated with hypertrophic obstructivel cardiomyopathy was proved.
Veselka
J
J
Oddĕlení srdecní chirurgie FN v Motole, Praha.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D002304:Cardiac Pacing, Artificial; D002312:Cardiomyopathy, Hypertrophic / Q000601:surgery / Q000628:therapy*; D017115:Catheter Ablation; D006346:Heart Septum / Q000601:surgery*; D006801:Humans; D014700:Verapamil / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D014700:Verapamil